MaxCyte (MXCT) Competitors

4imprint Group (LON:FOUR) and MaxCyte (LON:MXCT) are both small-cap communication services companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Do analysts rate FOUR or MXCT?

4imprint Group currently has a consensus target price of GBX 7,365, indicating a potential upside of 31.99%. Given 4imprint Group's stronger consensus rating and higher probable upside, analysts plainly believe 4imprint Group is more favorable than MaxCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4imprint Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
MaxCyte	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more risk and volatility, FOUR or MXCT?

4imprint Group has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Is FOUR or MXCT more profitable?

4imprint Group has a net margin of 8.20% compared to MaxCyte's net margin of -77.97%. 4imprint Group's return on equity of 92.73% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4imprint Group	8.20%	92.73%	35.62%
MaxCyte	-77.97%	-15.33%	-11.07%

Does the media refer more to FOUR or MXCT?

In the previous week, 4imprint Group had 1 more articles in the media than MaxCyte. MarketBeat recorded 1 mentions for 4imprint Group and 0 mentions for MaxCyte. 4imprint Group's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
4imprint Group	Neutral
MaxCyte	Neutral

Which has stronger earnings & valuation, FOUR or MXCT?

4imprint Group has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than 4imprint Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4imprint Group	£1.36B	1.16	£111.40M	£2.32	2,405.17
MaxCyte	£45.44M	9.34	-£35.43M	-£0.26	-1,553.85

Do institutionals & insiders have more ownership in FOUR or MXCT?

83.3% of 4imprint Group shares are held by institutional investors. Comparatively, 70.5% of MaxCyte shares are held by institutional investors. 2.1% of 4imprint Group shares are held by insiders. Comparatively, 1.5% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community favor FOUR or MXCT?

4imprint Group received 164 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 72.71% of users gave 4imprint Group an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.

Company	Underperform	Outperform
4imprint Group	Outperform Votes 317 72.71%	Underperform Votes 119 27.29%
MaxCyte	Outperform Votes 153 68.92%	Underperform Votes 69 31.08%

Summary

4imprint Group beats MaxCyte on 15 of the 17 factors compared between the two stocks.